

# Ubiquitin-Activating Enzyme (E1) Localised in Human Placenta

## UBİKÜİTİN AKTİVE EDİCİ ENZİM (E1) İNSAN PLASENTASINDA LOKALİZE OLMUŞTUR

Ahmet KIZILTUNÇ\*, Fatih AKÇAY\*, Sedat KADANALI\*\*, Yaşar Nuri ŞAHİN\*

Depts. of \*Biochemistry, \*\*Gynecology, Medical School of Atatürk University, Erzurum, TURKEY

### Summary

As the first enzyme in the ubiquitin (Ub) system, the ubiquitin-activating enzyme (E1) plays a pivotal role in all pathways of protein ubiquitination. E1 was purified from human placenta, and its tissue distribution was investigated. The enzyme was purified by diethyl amino ethyl cellulose (DEAE-cellulose) and affinity chromatography from the material in question. The purity of the purified E1 enzyme was tested by sodium dodecyl sulfide-polyacrylamide gel electrophoresis (SDS-PAGE). An antibody against E1 enzyme was produced in rabbits for the use in immunohistochemical studies. The specificity of the antibody produced was tested with enzyme-linked immunosorbent assay (ELISA). Tissue sections were stained immunohistochemically with the antibody produced for the investigation of the presence of E1 enzyme in placental sections. It was concluded that E1 enzyme is present in placental tissue, since some of the decidual cell cytoplasm showed staining. That E1 enzyme is localised in human placenta may indicate multiple roles of ubiquitination pathway in this tissue.

**Key Words:** Ubiquitin activating enzyme. Placenta

T Klin J Med Res 1998, 16:11-15

Ubiquitination, being a covalent modification of cellular proteins, has a role in a variety of physiological processes, the best understood of which is the ubiquitin-dependent degradative pathway (1). After ubiquitination, the proteins are targeted for degradation. A three-step mechanism for Ub-protein conjugate formation has been proposed (2). After activation to a thiol ester via tightly bound Ub adenylate by E1, Ub is transferred to thiol groups

Received: June 05, 1998

Correspondence: Ahmet KIZILTUNÇ  
Department of Biochemistry,  
Medical School of Atatürk University,  
25240 Erzurum-TURKEY

T Klin J Med Res 1998, 16

### Özet

Ubikuitin (Ub) sisteminde ilk enzim olan ubikuitin aktive edici enzim (E1) protein ubikuitinasyonunun bütün yollarında temel rol oynar. E1 insan plasentasından saflaştırıldı ve doku dağılımı araştırıldı. Enzim material içeriğinden afinite kromatografisi ve dietil-amino-etil selüloz (DEAE-selüloz) ile saflaştırıldı. Saflaştırılmış E1 enziminin saflığı sodyum dodesil sülfatpoliakrilamidjel elektroforezi ile (SDS-PAGE) test edildi. İmmunohistokimyasal çalışmalarda kullanmak için E1 enzime karşı antikor tavşanlarda üretildi. Üretilmiş antikorun spesifitesi enzim-linked immunosorbent metodu (ELİSA) ile test edildi. Placenta kesitlerinde E1 enziminin varlığını araştırmak için doku kesitleri üretilmiş antikor ile immunohistokimyasal olarak boyandı.

Desidual hücre sitoplazmalarının bazıları boyandığından dolayı, E1 enziminin placenta dokusunda olduğu sonucuna varıldı. İnsan plasentasında E1 enziminin lokalize olması bu dokuda ubikuitinasyon yolunun mu/iple rolünü göstermektedir.

**Anahtar Kelimeler:** Ubikuitin aktive edici enzim. Placenta

T Klin Araştırma 1998, 16: 11-15

on a number of low-molecular weight proteins, collectively termed Ub carrier proteins (E2s). One or more of the E2-Ub thiol esters then donates Ub to a protein amino group in a reaction catalyzed by Ub-protein ligase (E3). Protein molecules can be multiply ubiquitinated even at very low extents of protein reaction, suggesting that Ub transfer may be processive (3). The first reaction which is catalysed by E1 in Ub conjugation is the activation of Ub to a high-energy intermediate. The Ub-activating enzyme catalyzes the activation of Ub in the three reversible steps. There are two active sites within the E1 molecule, allowing it to accommodate two Ub moieties at a time, with a new Ub forming an adenylate intermediate as the previous one is trans-

ferred to the thiol site (4). The purified enzyme has an apparent  $M_r=210$  kDa and appears to be composed of two subunits of  $M_r=105$  kDa (5). In our early study, we have found that ethilmaleimid, EDTA and mercurynitrate were inhibitors of the enzyme, optimum pH of the enzyme was 7 and optimum temperature was  $35^\circ\text{C}$  (6).

In the literature review related to this subjects, it was found that E1 enzyme was studied in yeast (7), wheat (8) and some tissues of human being such as blood, skeleton and lungs (9,10). To the best of our knowledge, we could not find any investigation related to placenta. In this study, therefore, we aimed to investigate whether E1 is present in placenta and the presence of cellular protein degradation in this tissue which provides a relation between the mother and the fetus.

### Materials and Methods

Human E1:Ub-activating enzyme was purified from placenta according to Ciechanover method of purification of Ub-activating from erythrocytes and reticulocytes and according to methods used by Scheider, Cuatrecasas, and Kohn (11-15). The placenta (weighing 700 gr) was washed three times with 150 mM KCl +200  $\mu\text{M}$  mercaptoethanol solution. This tissue was divided into four equal parts (each 175 gr) and then was homogenised in 20 mM Tris-HCl +1 mM EDTA and 2% glycerol solution (30v/5v/10v) with previously cooled cycle blend homogenisator (Fisher). The homogenate was centrifuged at  $13000 \times g$  and the supernatant was collected. This 200 mL supernatant was incubated in 150 mL 0.2 mM 2,4-dinitrophenol and 150 mL 20 mM 2-deoxyglucose solutions for 2 hours at  $37^\circ\text{C}$ ; then it was treated with 1 mM 2 L DTT solution and centrifuged at  $80\,000 \times g$  for 90 minutes and the supernatant was taken (fraction I). Sixty mL of supernatant was loaded onto  $3 \times 74$  cm DEAE-cellulose (Whatman, DE-52) which was pretreated with 3 mM  $\text{K}_2\text{P}_0_4$  (pH=7). Unbounded molecules were eluted with 150 mL 3 mM  $\text{K}_2\text{P}_0_4$  containing 1 mM DTT. After that, the bounded molecules were eluted with the help of 150 mL eluting solution containing 0.5 mM KCl+1 mM DTT and 10 mM Tris-HCl (pH=7.2). After precipitation of the eluate with  $(\text{NH}_4)_2\text{SO}_4$  on dialysis, the solution was collected (fraction II). Ten gr of sepharose 4B complex was

swollen with distilled water and the remaining water was poured. Four hundred mL Ub (Sigma) functioning as a ligand, 1 mg a 6-carbon N-hydroxy-succinamide (Sigma) as a spacer ami, 200 mL glacial acetic acid, 800 mL Tris-HCl (pH=7.2) and swollen sepharose 4B were mixed with a stirrer at a low rate over night at  $+4^\circ\text{C}$ . The homogenous mixture obtained was packed into columns (Pharmacia,  $2 \times 15$  cm) and was washed three times, each time using 0.1 M Na-acetate (pH=4) containing 1 M NaCl and 0.1 M Tris-HCl (pH=8) solutions, respectively. The column was balanced with a buffer solution [0.2 mM DTT+5 mM  $\text{MgCl}_2$ +2 mM ATP and 50 mM Tris-HCl (pH=7.2)]. Thirty mL of fraction II solution was mixed with 50 mM Tris-HCl, 5 mM ATP, 10 mM  $\text{MgCl}_2$ , 0.2 mM DTT and 5 U/mL inorganic pyrophosphatase (Sigma) and this homogenous solution obtained was loaded onto the column. The column was washed with the buffer solution above followed by 50 mM Tris-HCl (pH=7.2) containing 1 M KCl. This procedure was repeated 3 times. The bounded molecules were eluted with the aid of 50 mM Tris-HCl (pH=7.2) solution containing 2 mM AMP (Sigma) and 0.04 mM NaPPj (Sigma). Protein concentration was determined by the method of Lowry et al. (16) using bovine serum albumin as standard. The purity of the enzyme was tested with SDS-PAGE (17). The protein contents of fraction II solution and eluate obtained from the column (E1 protein) were found as 25-30 mg/mL and 3-5 mg/mL, respectively.

**Anti-E1 mAbs:** For obtaining mAbs to human E1, rabbits were subcutaneously injected with 50  $\mu\text{g}$  of purified E1 protein in 100  $\mu\text{L}$  acetic acid, 800 mL Tris-HCl (pH=7.2) and 1 mL Freund's adjuvant (Sigma). This procedure was repeated three times in a 20-day period. Twenty five days after the last injection, blood samples were taken and incubated at  $37^\circ\text{C}$  for one night, then the fust rAb in serum obtained was used in immunohistochemical studies. The specificity of anti-E1 mAb was tested by ELISA.


**Immunohistochemical study:** Immunohistochemical studies were performed according to peroxidase-antiperoxidase labelling method (18). Tissue sections with the thickness of 6-7 mm fixed on the lamel were incubated in 80% xylene and 90% ethanol solutions. Then, incubation was car-

ried out in peroxidase inhibiting solution (2% H<sub>2</sub>O<sub>2</sub>+60% methanol) for 20 minutes. After being washed with water, tissue sections were incubated in 100% fonnice acid solution for 3 minutes and in blocking solution (10% fetal calf serum+0.15 M NaCl+0.01 M Na<sub>2</sub>HPO<sub>4</sub>, pH=7.2) at 4 °C for 5 minutes, respectively. One hundred UL of anti-EI mAbs (1:500 dilution) was added on tissue sections and incubated at 4 °C for 15 hours. After washing, 100 uX of peroxidase conjugating second mAb (1:200 dilution, Sigma) was added on tissue sections and incubated at 4 °C for 15 hours. The dilutions of mAbs were performed with the 10% phosphate buffered saline solution (10 mM Na<sub>2</sub>PO<sub>4</sub>+0.9% NaCl, pH=7.2). After washing process, incubation was continued in staining solution (0.15% NaCl+0.01 M Na<sub>2</sub>HPO<sub>4</sub>.1S gr 3,3'-diaminobenzidin+0.2 gr imidazole+45 UL H<sub>2</sub>O<sub>2</sub>, pH=7.2) for 10 minutes and washing was done with 0.5% CuSO<sub>4</sub>+0.9% NaCl. Following a ten-minute incubation in 70% hemotoxyline solution, the tissue sections were incubated in acid-alcohol solution (0.5% HCl+70% ethanol) for 10 minutes. After being washed with tapering water, tissue sections were passed through 50%, 95%, 100% ethanol solutions and 80% xylene solutions for 3 minutes each, respectively. Tissue sections were dyed and their photographs were taken.


**Results and Discussion**

Recent studies have shown that the conjugation of Ub with proteins may play an important role in the energy-dependent degradation of intracellular proteins (19). It is possible that disruption of the cytoskeleton in neurodegenerative disorders by improper localization of Ub system components or the appearance of aberrant protein conjugation could lead to altered proteolytic processing and contribute to the pathology of neurological disease. Indeed, Ub conjugates have been found to be associated with neurofibrillary tangles of Alzheimer's disease (20), Lewy bodies in Parkinson's disease, and Pick's bodies in Pick's disease (21). Both EI and Ub conjugates colocalize with actin fibers, intermediate filaments, and microtubules (1).


EI was >95% purified from human placenta via immobilized Ub affinity chromatography yielding a single polypeptide of -105 kDa after



**Figure 1.** Purified human placenta EI. Coomassie blue stain of 14% SDS/PAGE analysis of human EI purified from placenta. Lane 1: a) Catalase (230 kDa)\*, b) Purified EI, c) Phosphorylase b (92,5 kDa)\*; Lane 2: a) Catalase (230 kDa), d) Myosin (200 kDa)\*, e) b-Galactosidase (116 kDa)\*, c) Phosphorylase b \*Molecular markers (Sigma).



**Figure 2.** Results of specificity of mAbs produced in rabbits.



**Figure 3.** Immunohistochemical localisation of EI. As mentioned in Materials and Methods section, the tissue was fixed and dyed, (x 400).

SDS/PAGE (Figure 1). Monoclonal antibodies from rabbits were raised against highly purified EI from human placenta. When tested with ELISA, anti-EI mAbs gave a specific reaction with EI antigen (Figure 2). We performed an immunohistochemical study of the distribution of Ub activating enzyme on the tissue section (Figure 3). When the first antibody, produced in our laboratory, and the second mAbs, commercially provided, were poured on tissue sections, these Abs reacted with EI antigens and staining was achieved, cytoplasm of decidual cells had positive staining indicating that EI enzyme is present in this tissue.

Protein turnover rates vary from tissue to tissue, and the relative tissue contribution to total protein turnover is altered by aging, disease, and changes in dietary protein intake. Several proteins have short turnover times, sometimes less than 1

hour. During periods of growth, pregnancy, lactation, or recovery from illness, protein requirement increases. Trausch et al (22) showed the localisation of EI enzyme both in cytoplasmic and in nuclear compartments of some different eukaryotic cells (HeLa, Smooth muscle A7r5, choriocarcinoma BeWo, PtK1, and Chinese hamster ovary (CHO) E36). In addition, they also found that this enzyme was associated with actin filaments, tubulin and intermediate filaments in cytoplasm of CHO and ptK1 cells. Cook and Chock (23) have described EI as being concentrated in nuclei of rat brain and liver. In our study, cytoplasm of decidual cells showed positive staining. The variable distribution of EI in different cell types including placenta, including its apparent cytoskeletal association, suggests pleiotropic functions of this enzyme and the Ub-conjugating system (22-24).

Thus, we have defined the immunolocalization of EI in human placenta, within cytoplasm of decidual cells. It is possible that EI and other components of the Ub system may play distinct, essential roles by localizing different subcellular compartments within the cell. As a result, this study showed that EI enzyme is present in placental tissue. Further studies are required to clarify the relation Ub-activating enzyme and placental state.

## REFERENCES

1. Finley D and Chau V. Ubiquitination. *Annu Rev Cell Biol* 1991; 7:25-69.
2. Hershko A, Heller H, Elias S and Ciechanover A. Components of Ubiquitin-protein ligase system. *J Biol Chem* 1983; 258: 8206-14.
3. Hershko A, Ciechanover A, Heller H, Haas AL, Rose IA. () Proposed role of ATP in protein breakdown Conjugation of proteins with multiple chains of the polypeptide of ATP-dependent proteolysis: *Proc Natl Acad Sci* 1980; 77:1783-86.
4. Haas AL, Rose IA. The mechanism of Ubiquitin activating enzyme. *J Biol Chem* 1982; 257:10329-337.
5. Ciechanover A, Elias S, Heller H, Hershko A. Covalent affinity purification of Ubiquitinating-activating enzyme. *The J Biol Chem* 1982; 257:2537-42.
6. Kiziltunc A, Pirim I, Sahin YN. Obtaining of ubiquitin activating enzyme and kinetic features. *T Clin J Med Sci* 1995; 15:260-4.
7. McGrath JP, Jentsch S, Varshavsky A. UBA 1 an essential yeast gene encoding ubiquitin-activating enzyme. *EMBO J* 1991; 10(1):227-36.

8. Hatfield PM, Callis J, Vierstra R. () Cloning of ubiquitin-activating enzyme from wheat and expression of a functional protein in *Escherichia coli*. *J Biol Chem* 1990; 265:15813-17.
9. Handley PM, Mueckler N, Siegel R, Ciechanower A, and Schwartz AL. Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. *Proc Natl Acad Sci USA* 1991; 88: 258-62.
10. Zacksenhaus E, Shcinin R. Molecular cloning primary structure and expression of the human X linked A1S9 gene cDNA which complements the ts A1S9 mouse L cell defect in DNA replication. *EMBO J* 1990; 9(9):2923-29.
11. Scheider R, Eckerskon C, Lottspeich F and Schweiger M. The human ubiquitin carrier protein E2 (17kDa) is homologous to the yeast DNA repair gene, RAD6. *EMBO J* 1990; 9(5): 1431-35.
12. Cuatrecasas P, Wilchek M, Anfinsen CB. Selective enzyme purification by affinity chromatography. *Proc Nat Acad Sci* 1968; 61: 636-43.
13. Kohn J, Wilchek M. A colorimetric method for monitoring activation of sepharose by cyanogen bromide. *Biochem \* Biophys Res Commun* 1978; 7-14.
14. Ciechanover A, Elias S, Heller H and Hershko A. Covalent affinity purification of ubiquitin-activating enzyme. *J Biol Chem* 1982; 257:2537-42.
15. Ciechanover A, Hod Y, Hershko A. A heat-stable polypeptide of an ATP-dependent proteolytic system from reticulocytes. *Biochem Biophys Res Commun* 1978; 81(4): 1100-05.
16. Lowry OH, Roscrough NJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193:265.
17. Laemmli DK. Cleavage of structural proteins during in assembly of the head of bacteriophage T4, *Nature London*. 1970; 227: 680.
18. Johnstone A, Thorpe R. *Immunochemistry in practice*. Blackwell Scientific Publications 1987; 261-88.
19. Goldstein G, Scheid M, Hammerling U, Boyse EA, Schlesinger DH and Niall HD. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cell. *Proc Natl Acad Sci USA* 1975; 72: 11-5.
20. Shaw G and Chau V. Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain. *Proc. Natl. Acad. Sci. USA*. 1988; 85:2854-58.
21. Lowe J and Mayer RJ. Ubiquitin, cell stress and diseases of the nervous system. *Neuropathol Appl Neurobiol* 1990; 16:281-91.
22. Trausch JS, Grenfell SJ, Handley-Gearhart PM, Ciechanover A, Schwartz AL. Immunofluorescent localization of the ubiquitin-activating enzyme, E1, to the nucleus and cytoskeleton. *American Physiological Society* 1993; 93:93-102.
23. Cook JC, Chock PB. Immunocytochemical localization of ubiquitin-activating enzyme in the cell nucleus. *Biochem Biophys Res Commun* 1991; 174(2): 564-71.
24. Schwartz AL, Trausch JS, Ciechanover A, Slot JW, Geuze H. () Immunoelectron microscopic localization of the ubiquitin-activating enzyme E1 in HepG2 cells. *Proc Natl Acad Sci* 1992; 89: 5542-44.